Drug costs in the management of metastatic castration-resistant prostate cancer in Canada

BACKGROUND: For Canadian men, prostate cancer (PCa) is the most common cancer and the 3rd leading cause of cancer mortality. Men dying of PCa do so after failing castration. The management of metastatic castration-resistant prostate cancer (mCRPC) is complex and the associated drug treatments are in...

Descripción completa

Detalles Bibliográficos
Autores principales: Dragomir, Alice, Dinea, Daniela, Vanhuyse, Marie, Cury, Fabio L, Aprikian, Armen G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4099156/
https://www.ncbi.nlm.nih.gov/pubmed/24927758
http://dx.doi.org/10.1186/1472-6963-14-252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4099156/
https://www.ncbi.nlm.nih.gov/pubmed/24927758
http://dx.doi.org/10.1186/1472-6963-14-252

Ejemplares similares